Compare Abbott India with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs LUPIN - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA LUPIN ABBOTT INDIA/
LUPIN
 
P/E (TTM) x 56.1 -78.3 - View Chart
P/BV x 16.6 2.3 712.3% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 ABBOTT INDIA   LUPIN
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-19
LUPIN
Mar-19
ABBOTT INDIA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs8,834986 896.0%   
Low Rs5,458720 757.6%   
Sales per share (Unadj.) Rs1,731.1369.5 468.5%  
Earnings per share (Unadj.) Rs211.913.4 1,580.9%  
Cash flow per share (Unadj.) Rs219.937.4 588.2%  
Dividends per share (Unadj.) Rs65.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs945.2303.7 311.2%  
Shares outstanding (eoy) m21.25452.49 4.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.12.3 178.8%   
Avg P/E ratio x33.763.6 53.0%  
P/CF ratio (eoy) x32.522.8 142.4%  
Price / Book Value ratio x7.62.8 269.1%  
Dividend payout %30.70-   
Avg Mkt Cap Rs m151,848386,064 39.3%   
No. of employees `0003.517.7 19.7%   
Total wages/salary Rs m4,35631,513 13.8%   
Avg. sales/employee Rs Th10,555.59,453.8 111.7%   
Avg. wages/employee Rs Th1,249.91,782.0 70.1%   
Avg. net profit/employee Rs Th1,292.2343.0 376.7%   
INCOME DATA
Net Sales Rs m36,786167,182 22.0%  
Other income Rs m1,1333,640 31.1%   
Total revenues Rs m37,919170,822 22.2%   
Gross profit Rs m6,04728,822 21.0%  
Depreciation Rs m16910,850 1.6%   
Interest Rs m233,078 0.7%   
Profit before tax Rs m6,98918,534 37.7%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m0-3,400 0.0%   
Tax Rs m2,4859,017 27.6%   
Profit after tax Rs m4,5036,066 74.2%  
Gross profit margin %16.417.2 95.4%  
Effective tax rate %35.648.7 73.1%   
Net profit margin %12.23.6 337.4%  
BALANCE SHEET DATA
Current assets Rs m27,610138,536 19.9%   
Current liabilities Rs m8,56961,299 14.0%   
Net working cap to sales %51.846.2 112.0%  
Current ratio x3.22.3 142.6%  
Inventory Days Days6084 71.9%  
Debtors Days Days27112 24.4%  
Net fixed assets Rs m1,057127,516 0.8%   
Share capital Rs m213905 23.5%   
"Free" reserves Rs m19,873136,517 14.6%   
Net worth Rs m20,086137,422 14.6%   
Long term debt Rs m066,417 0.0%   
Total assets Rs m29,409279,494 10.5%  
Interest coverage x311.67.0 4,438.2%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x1.30.6 209.1%   
Return on assets %15.43.3 470.4%  
Return on equity %22.44.4 508.0%  
Return on capital %34.98.9 391.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36959,414 0.6%   
Fx outflow Rs m4,91822,282 22.1%   
Net fx Rs m-4,54937,132 -12.3%   
CASH FLOW
From Operations Rs m4,99116,660 30.0%  
From Investments Rs m-2,570-32,825 7.8%  
From Financial Activity Rs m-1,4287,441 -19.2%  
Net Cashflow Rs m993-8,724 -11.4%  

Share Holding

Indian Promoters % 0.0 46.6 -  
Foreign collaborators % 75.0 0.2 37,500.0%  
Indian inst/Mut Fund % 7.9 11.3 69.9%  
FIIs % 0.1 31.9 0.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 10.1 169.3%  
Shareholders   18,270 98,259 18.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   NOVARTIS  JUBILANT LIFE SCIENCES  BIOCON   IPCA LABS  NATCO PHARMA  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 428 Points Higher; Energy and Healthcare Stocks Witness Buying(Closing)

Indian share markets continued their momentum during closing hours and ended their trading session on a positive note today.

Related Views on News

TORRENT PHARMA at All Time High; BSE HEALTHCARE Index Up 2.0% (Market Updates)

Feb 19, 2020 | Updated on Feb 19, 2020

TORRENT PHARMA share price has hit an all time high at Rs 2,286 (up 6.0%). The BSE HEALTHCARE Index is up by 2.0%. Among the top gainers in the BSE HEALTHCARE Index today are TORRENT PHARMA (up 6.0%) and ABBOTT INDIA (up 3.7%). The top losers include DISHMAN CARBOGEN AMCIS LTD (down 0.1%) and SYNGENE INTERNATIONAL (down 0.3%).

WOCKHARDT Surges by 5%; BSE HEALTHCARE Index Up 1.5% (Market Updates)

Feb 19, 2020 | Updated on Feb 19, 2020

WOCKHARDT share price has surged by 5% and its current market price is Rs 357. The BSE HEALTHCARE is up by 1.5%. The top gainers in the BSE HEALTHCARE Index are WOCKHARDT (up 5.2%) and AUROBINDO PHARMA (up 15.7%). The top losers are SUN PHARMA and FORTIS HEALTHCARE (down 0.1%).

GRANULES INDIA at All Time High; BSE HEALTHCARE Index Up 1.5% (Market Updates)

Feb 19, 2020 | Updated on Feb 19, 2020

GRANULES INDIA share price has hit an all time high at Rs 189 (up 4.2%). The BSE HEALTHCARE Index is up by 1.5%. Among the top gainers in the BSE HEALTHCARE Index today are GRANULES INDIA (up 4.2%) and ABBOTT INDIA (up 4.2%). The top losers include SUN PHARMA and FORTIS HEALTHCARE (down 0.1%).

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years)(Profit Hunter)

Feb 11, 2020

A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.

How to Become a One Stock Crorepati(Profit Hunter)

Feb 6, 2020

A little known Indian stock that is set to turn around its own fortunes, and your wealth, if you just have the foresight to get in on time...

Will Algo Traders Take Away All Your Profits?(Fast Profits Daily)

Feb 11, 2020

How to fight back against algo trading systems.

How to Use Stop Losses in Your Trading(Fast Profits Daily)

Feb 13, 2020

There's more to stop losses than just limiting a trading loss. Find out more...

No Change in My Long-Term View on the Rebirth of India Stocks(The 5 Minute Wrapup)

Feb 6, 2020

Why the recent post budget volatility has not affected my bullish view on the Rebirth of India stocks.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Feb 19, 2020 03:35 PM

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS